XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation

NCT05875402 | Unknown DMC

• 1 other identifier: XKDCT080
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to assessing the safety and tolerability of XKDCT080 cells against recurrent or refractory solid tumors with GCC positivity.This experiment proposes to enroll 9-18 patients, the experimental drug is a chimeric antigen receptor T cell preparation targeting GCC. Secondary purpose of the study

1. 1.Evaluate the pharmacokinetic characteristics of XKDCT080 cells after intravenous infusion into GCC-positive patients with recurrent or refractory solid tumors;
2. 2.Preliminary Evaluation of the Effectiveness of XKDCT080 Cells in Patients with Recurrent or Refractory Solid Tumors Positive for GCC;
3. 3.Explore the relationship between cytokines and therapeutic efficacy in patients with recurrent or refractory solid tumors who are positive for GCC after intravenous infusion of XKDCT080 cells.

Conditions

Colon Cancer

Keywords

Chimeric Antigen

Outcome Measures

Primary Outcomes (1)

• Adverse Events (AE)

  To characterize the safety profile of XKDCT080 in patients with advanced solid tumor as assessed by incidence of adverse events

  12 months]

Study Arms (1)

XKDCT080 treatment for patients with GCC target positivity

EXPERIMENTAL

Drug: XKDCT080 (chimeric antigen receptor T cell preparation targeting GCC) Dosage form: Cell suspension Dose: 30-50mL/bag Medication method: intravenous drip Frequency: Once

Drug: Chimeric antigen receptor T cell preparation targeting GCC

Interventions

Chimeric antigen receptor T cell preparation targeting GCC DRUG

Chimeric antigen receptor T cell preparation targeting GCC

XKDCT080 treatment for patients with GCC target positivity

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To be eligible for the study, patients must meet ALL of the following criteria prior to participation:
• Age range from 18 to 75 years (including threshold), regardless of gender；
• Solid tumors with positive expression of guanylate cyclase (GCC) were detected by immunohistochemistry in tumor tissue；
• Patients with solid tumors who have failed standard treatment, are intolerant to standard treatment, have no standard treatment options, or have relapsed；
• At least one measurable lesion (non lymph node lesion with a length diameter of ≥ 10mm and lymph node lesion with a short diameter of ≥ 15mm) is required using the RECIST 1.1 standard；
• ECOG physical condition score 0-2；
• Blood routine standard: hemoglobin ≥ 90g/L (no blood transfusion within 14 days), neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 80 × 109/L；
• Blood biochemistry should meet the following standards: total bilirubin ≤ 1.5 × ULN (upper limit of normal value), ALT and AST ≤ 2.5 × ULN (excluding patients with liver metastasis); ALT and AST ≤ 5 in patients with liver metastasis × ULN； Serum creatinine ≤ 1 × ULN, glomerular filtration rate\>50mL/min (GFR=\[(140 age) × weight × (0.85 female)\]/(72 × Scr), serum lipase and amylase\<1.5 × ULN (upper limit of normal value), albumin ≥ 2.8g/dL;
• Cardiac ejection fraction\>50%；
• No hemorrhagic diseases or coagulation disorders；
• The expected survival period is ≥ 12 weeks；
• The subjects voluntarily participated in the study and signed an informed consent form.

You may not qualify if:

• Patients with any of the following criteria will not be allowed to participation:
• Pregnant or lactating women;
• Participate in other drug clinical trials within 4 weeks before screening;
• There are uncontrollable cardiovascular and cerebrovascular diseases within the first 6 months of screening, such as heart failure or others;
• Have a history of drug abuse and are unable to quit or have a history of mental disorders;
• Has received any immune cell therapy in the past;
• Fungi, bacteria, viruses, or other infections that cannot be controlled or require antibiotic treatment;
• Hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, and HBV-DNA\>500 IU/mL; Patients with positive hepatitis C virus (HCV) antibodies and positive peripheral blood HCV RNA; People who are positive for human immunodeficiency virus (HIV) antibodies; Syphilis antibody positive individuals;
• Allergies or intolerance to research drugs such as Tozumab, Fludarabine, Cyclophosphamide, Capecitabine, and other gonorrhea clearing drugs selected by the researchers;
• Active autoimmune diseases such as systemic lupus erythematosus or others within the first 3 months of screening;
• Suffering from known symptomatic central nervous system (CNS) diseases;
• The surgery was performed within 2 weeks before the single collection and the researcher believes that it may affect the safety of patient safety;
• There was a history of deep vein thrombosis or pulmonary embolism 6 months before enrollment;
• Used drugs that affect immune function one month before screening;
• Previously received GCC targeted therapy;

Sponsors & Collaborators

• The Affiliated Hospital of Qingdao University: lead

Study Sites (1)

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

RECRUITING

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases

Study Officials

• jing wang, MD

  The Affiliated Hospital of Qingdao University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

jing wang, MD

CONTACT

18661805686; wangstella5@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chief physician

Study Record Dates

• First Submitted: April 25, 2023
• First Posted: May 25, 2023
• Study Start: April 1, 2023
• Primary Completion: December 28, 2023
• Study Completion: May 30, 2025
• Last Updated: May 25, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)